{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:15:40Z","timestamp":1784132140757,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Immune checkpoint inhibitors can cause various adverse effects. Recently it has been shown that Vogt\u2013Koyanagi\u2013Harada (VKH) disease-like uveitis can occur in patients treated with nivolumab.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 69-year-old man developed bilateral panuveitis after nivolumab treatment for recurrent hypopharyngeal cancer. Slit lamp examination revealed bilateral granulomatous keratic precipitates, anterior chamber cells and partial synechiae. Fundus examination revealed bilateral optic disc edema and diffuse serous retinal detachment. His human leukocyte antigen (HLA) typing showed HLA-DRB1*04:05 allele. A lumbar puncture did not demonstrate pleocytosis. Bilateral sub-tenon injections of triamcinolone acetonide were initiated. As his panuveitis did not regress completely, steroid pulse therapy was administered. That therapy led to the resolution of his serous retinal detachment and to rapid improvement in his vision. Following this, we treated him with 50\u2009mg\/day of prednisolone for 1\u2009week and then reduced it by 5\u2009mg every week. No bilateral uveitis relapse had occurred by his 3-month follow-up; however, he subsequently died because of his cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>To our knowledge, this is the first report of a patient with NVKH who underwent a lumbar puncture. Unlike VKH, our case did not show meningismus or pleocytosis. NVKH may, therefore, have a different etiology from VKH.<\/jats:p>\n<jats:p>In cases of NVKH with posterior uveitis, steroid pulse therapy may be considered as a treatment option, as it is in VKH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01519-5","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T11:02:54Z","timestamp":1592996574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Vogt\u2013Koyanagi\u2013Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Ryo","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsukata","family":"Kawagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"1519_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"issue":"6","key":"1519_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, et al. Checkpoint inhibitor immune therapy systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063\u201378.","journal-title":"Retina"},{"issue":"5","key":"1519_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647\u201352.","journal-title":"Am J Ophthalmol"},{"key":"1519_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1519_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","volume":"44","author":"T Arai","year":"2017","unstructured":"Arai T, Harada K, et al. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2017;44(8):975\u20136.","journal-title":"J Dermatol"},{"issue":"5","key":"1519_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2018","unstructured":"Matsuo T, Yamazaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2018;5(5):694\u2013700.","journal-title":"Clin Case Rep"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol. 2018;45:735\u20137.","journal-title":"J Dermatol"},{"issue":"1","key":"1519_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00262-018-2260-7","volume":"68","author":"W Wang","year":"2019","unstructured":"Wang W, Lam WC, et al. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2019;68(1):85\u201395.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1519_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, et al. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10(1):67\u201374.","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"1519_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/bjo.78.3.223","volume":"78","author":"Y Shindo","year":"1994","unstructured":"Shindo Y, Inoko H, et al. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78(3):223\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1519_CR12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajo.2006.01.017","volume":"141","author":"H Keino","year":"2006","unstructured":"Keino H, Goto H, et al. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;141(6):1140\u20132.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1519_CR13","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.4049\/jimmunol.165.12.7323","volume":"165","author":"K Yamaki","year":"2000","unstructured":"Yamaki K, Gocho K, et al. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165(12):7323\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"1519_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","volume":"256","author":"CD Conrady","year":"2018","unstructured":"Conrady CD, Larochelle M, et al. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):187\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"1519_CR15","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.4103\/ijo.IJO_1161_19","volume":"67","author":"C Navarro-Perea","year":"2019","unstructured":"Navarro-Perea C, Garcia-Gonzalez J, et al. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol. 2019;67(12):2075\u20137.","journal-title":"Indian J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01519-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T23:29:29Z","timestamp":1624490969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01519-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01519-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. The authors declare that they adhered to the CARE guidelines\/methodology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}